IBIO Stock Price - iBio Inc. plunges again, as a COVID-19 vaccine seems out of reach

NYSEAMERICAN:IBIO falls another 5.13% to end the week in the red.
iBio Inc. falls behind competitors in the race for COVID vaccine.

NYSE:AMERICAN:IBIO has dropped a further 5.13% during Friday’s trading session, ending the week at $4.44 per share, representing a 17% decrease from the start of the week. The Biotech stock has had a rollercoaster run this week, with wild swings of a 5% gain one day and 11% losses the next. Ultimately, the losses outnumbered the gains and investors have been left wondering about the once-promising outlook of iBio-200 – the company’s second vaccine program.

Investors and analysts were bullish on the Texas-based company back when Lincoln Park Capital invested $50 million into the company ahead of their COVID vaccine research. However, little has changed for iBio Inc. since and now, the outlook seems unclear as traders approach the quarterly earnings call in mid-August. Markets may very well see iBio’s attempts at creating a vaccine fade into the background so the company can focus on something they are proven to be more efficient at handling mass production of medication or vaccines developed by other companies. If investors want to hang their hats on a long-term play, it should be with iBio as a manufacturer, not a creator.

iBio Stock Forecast

iBio does not have a history of exceeding quarterly estimates, so investors should remain cautious leading up to their earnings call. The volatility of these penny Biotech stocks is strong, and as seen earlier this week, any sort of news can cause violent upward or downward swings. The stock price seems to level out every time it hits the lows in the $4.30 range. However, if it does break that barrier on a downward trend, there is no telling how low it could go, the longer there is no announcement of a successful vaccine.

Share: Feed news

Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.

If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.

FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.

The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.